• Trials and Research

  Enrollment Complete in Phase 2 Trial Testing Temelimab

  Posted by MS News Today Moderator on February 26, 2021 at 10:15 am

  

  The study of temelimab has enrolled 42 people with relapsing MS whose disability progressed in the absence of relapses after treatment with rituximab. Click here to learn more.

  Are you following this study? What do you think of the findings so far?

  MS News Today Moderator replied 4 years, 4 months ago 0 Member · 0 Replies
• 0 Replies

Log In to Reply